West Pharmaceutical Services, Inc. (WST) Upgraded by Jefferies Group LLC to “Buy”
West Pharmaceutical Services, Inc. (NYSE:WST) was upgraded by investment analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating in a report released on Friday, Marketbeat Ratings reports. The brokerage currently has a $115.00 price target on the medical instruments supplier’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 19.90% from the company’s current price.
WST has been the subject of several other research reports. BidaskClub lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $98.52.
West Pharmaceutical Services (WST) traded up 4.61% on Friday, hitting $95.91. 761,446 shares of the company were exchanged. West Pharmaceutical Services has a 52 week low of $70.17 and a 52 week high of $99.91. The stock has a 50 day moving average of $87.41 and a 200 day moving average of $89.29. The company has a market capitalization of $7.10 billion, a price-to-earnings ratio of 41.16 and a beta of 1.13.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. The firm had revenue of $397.60 million during the quarter, compared to analyst estimates of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. West Pharmaceutical Services’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 EPS. Analysts predict that West Pharmaceutical Services will post $2.68 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of WST. Acrospire Investment Management LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $113,000. Citigroup Inc. raised its position in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the last quarter. Harfst & Associates Inc. purchased a new position in West Pharmaceutical Services in the 1st quarter worth about $186,000. Wolverine Trading LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $200,000. Finally, Nomura Holdings Inc. purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $201,000. 91.25% of the stock is owned by hedge funds and other institutional investors.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.